Recruiting

Nevisense Go

Sponsor:

Castle Biosciences Incorporated

Code:

NCT07645820

Conditions

Atopic Dermatitis

Eligibility Criteria

Sex: All

Age: 12 - 70+

Healthy Volunteers: Not accepted

Interventions

Nevisense electrical impedance spectroscopy

Study Details

Brief summary:

This study will collect skin measurements from people with atopic dermatitis (AD) using the investigational Nevisense Go device. Participants aged 12 to 89 years with a history of AD flares will use the device at home for about 90 days. Participants will complete device measurements, electronic diary entries, and up to five in-person study visits. The study is based on the idea that changes in skin barrier function may occur before an AD flare becomes visible or symptoms begin. Information collected during the study, including device measurements, diary entries, and investigator assessments, will be used to evaluate whether these changes may help estimate the likelihood of an AD flare before visible signs or symptoms occur.

Conditions

Atopic Dermatitis

Study ID

NCT07645820

Start date

Jun 4, 2026

Status verified date

Oct, 2026

Completion date

Dec 31, 2027

Anticipated

Primary completion date

Apr 1, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 12 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Participants may be eligible if they:

  • Are 12 to 89 years old.
  • Have been diagnosed with atopic dermatitis (eczema).
  • Have had at least one atopic dermatitis flare within the past 2 months.
  • Are willing and able to use the Nevisense Go device at home, complete an electronic symptom diary, and attend study visits.
  • If currently using systemic treatment for atopic dermatitis, have been on the same treatment for at least 3 months and do not plan to change treatment during the study.

Exclusion Criteria:

Participants may not be eligible if they:

  • Are unwilling or unable to avoid applying creams, lotions, ointments, or soap to measurement areas for 6 hours before measurements.
  • Do not have suitable skin areas for study measurements.
  • Have another skin condition that may affect study assessments.
  • Are pregnant.

Study Design

Enrollment

450 participants

Anticipated

Interventions and Outcome Measures

Interventions

Nevisense electrical impedance spectroscopy

The NevisenseGo device will collect skin measurements from people with atopic dermatitis (AD) to see if it can effectively predict a flare in disease.

Primary outcome measure

  • Relationship between skin measurements and subsequent atopic dermatitis flares [ Time Frame: Measurements taken over 90 days, 5 days a week ]
  • Develop and validate an algorithm using Nevisense Go EIS [ Time Frame: From enrollment until end of treatment at 90 days. ]

Central Contacts and Locations

Central contacts

Clare Johnson E VP Clinical Research

602-499-0301cjohnson@castlebiosciences.com

Locations

U.S. Dermatology Partners

Recruiting

Phoenix, Arizona, United States, 85006

Principal Investigator:

Margaret Kessler, MD

James Y. Wang MD, Inc

Recruiting

Los Angeles, California, United States, 90017

Principal Investigator:

James Y Wang, MD

U.S. Dermatology Partners Rockville

Recruiting

Rockville, Maryland, United States, 20850

Principal Investigator:

Benjamin Lockshin, MD, FAAD

Derm Research Institute, PLC

Recruiting

Caledonia, Michigan, United States, 49316

Principal Investigator:

Kristi Hawley, DO

U.S. Dermatology Partners Lee's Summit

Recruiting

Lee's Summit, Missouri, United States, 64064

Principal Investigator:

Mark Fleischman, MD, FAAD

Advanced Dermatology and Cosmetic Surgery - Henderson

Recruiting

Henderson, Nevada, United States, 89052

Principal Investigator:

Grace (Kim) Dowty, DO, FAOCD, FAAD

Las Vegas Dermatology

Recruiting

Las Vegas, Nevada, United States, 89144

Principal Investigator:

David Cotter, MD, PhD

StracSkin, PLLC

Recruiting

Portsmouth, New Hampshire, United States, 03801

Principal Investigator:

Abel Jarell, MD, FAAD

DCOL Center for Clinical Research

Recruiting

Longview, Texas, United States, 75605

Principal Investigator:

Blake Robbins, DO

Harrison Dermatology

Recruiting

Missouri City, Texas, United States, 77459

Principal Investigator:

Harrison Nguyen, MD, MBA, MPH, DTM&H FAAD

Jordan Valley Dermatology

Recruiting

South Jordan, Utah, United States, 84095

Principal Investigator:

Douglass Forsha, MD

Virginia Clinical Research, Inc

Recruiting

Norfolk, Virginia, United States, 23502

Principal Investigator:

Robert Pariser, MD

West Virginia Research Institute

Recruiting

Morgantown, West Virginia, United States, 26505

Principal Investigator:

Rola Gharib, MD

More Information

Sponsor

Castle Biosciences Incorporated

Last update posted

Oct 20, 2026

Last verified

Oct, 2026

Keywords

  • Electrical Impedance Spectroscopy
  • EIS
  • Atopic Dermatitis
  • Eczema
  • Flare
  • Skin barrier function
  • Flare Prediction
  • Dermatology
  • Nevisense Go
  • Skin Barrier Dysfunction

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-24. This information was provided to ClinicalTrials.gov by Castle Biosciences Incorporated on 2026-10-20. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.